Skip to main content

Advertisement

Table 1 DMBA-induced mammary gland tumor formation in WT, CORT-KO and SST-KO mice by whole-mount analysis

From: Lack of cortistatin or somatostatin differentially influences DMBA-induced mammary gland tumorigenesis in mice in an obesity-dependent mode

  WT CORT-KO SST-KO
  LF (n = 39) HF (n = 43) LF (n = 33) HF (n = 24) LF (n = 23) HF (n = 30)
Whole-mount analysis
Tumor 3 % 5 % 14 %## 13 % 4 %$ 3 %$
Hyperplasia 16 % 35 %** 10 % 25 %** 13 % 38 %***
Normal 81 % 60 %** 76 % 63 % 83 % 59 %**
Percentage of mice that were not included in the studya 35 % 24.5 % 21.4 % 40 % 30.3 % 23 %
  1. **p <0.01, ***p <0.001, for mice fed a low fat (LF) diet vs high fat (HF) diet (within the same genotype); ## p <0.01 in wild-type (WT) vs knockout (KO) mice (within the same diet group); $ p <0.05) in cortistatin (CORT)-KO vs somatostatin (SST)-KO (within the same diet group). aMice that died during the 3 weeks of 7, 12 dimethylbenz[α]anthracene (DMBA) administration or during the weeks immediately subsequent, due to the toxicity of this compound and/or the invasiveness of the method used to deliver DMBA, were not included in the study